-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On August 17, the official website of CDE showed that BeiGene's tislelizumab (trade name: Beizian) injection was approved by the Food and Drug Administration for the treatment of advanced malignant solid tumors
Tilelizumab (trade name: Baizean) is a humanized lgG4 anti-programmed death receptor 1 (PD-1) monoclonal antibody, designed to minimize Fcγ in macrophages Receptor binding
At present, Bizeran has been approved for 5 indications in China
On January 12, 2021, BeiGene and Novartis reached a cooperation and licensing agreement to develop, Production and commercialization of the anti-PD-1 antibody Bezean (Tilelizumab), with a total transaction value of up to 2.
On August 6, 2021, BeiGene announced its financial results for the second quarter and the first half of 2021.
In the first half of 2021, BeiGene's total revenue was 4.